PHASE-II STUDY OF ANGUIDINE IN GASTROINTESTINAL MALIGNANCIES - A SOUTHWEST ONCOLOGY GROUP-STUDY

  • 1 January 1982
    • journal article
    • research article
    • Vol. 66  (2) , 381-383
Abstract
The Southwest Oncology Group conducted a phase II study of anguidine in 134 patients with gastrointestinal malignancies. Anguidine was administered as a 4 h infusion at doses of 3.0 and 4.5 mg/m2 daily .times. 5. Response rates for patients with colon carcinoma were 22% (4 of 18 patients without previous chemotherapy) and 6% (4 of 63 patients with previous chemotherapy). There were no responses in patients with pancreatic cancer (4 patients) or gastric cancer (6). Toxic effects included thrombocytopenia (19.8%), leukopenia (18.8%), nausea and vomiting (49%), hypotension (37%) and confusion (12%). Antitumor activity of anguidine in patients with colon cancer may be similar to that of 5-FU [5-fluorouracil], but nonhematologic toxicity is substantial.

This publication has 2 references indexed in Scilit: